317 related articles for article (PubMed ID: 31318724)
1. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
2. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.
Schiller CB; Braciak TA; Fenn NC; Seidel UJ; Roskopf CC; Wildenhain S; Honegger A; Schubert IA; Schele A; Lämmermann K; Fey GH; Jacob U; Lang P; Hopfner KP; Oduncu FS
Oncotarget; 2016 Dec; 7(50):83392-83408. PubMed ID: 27825135
[TBL] [Abstract][Full Text] [Related]
3. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Hassenrück F; Knödgen E; Göckeritz E; Midda SH; Vondey V; Neumann L; Herter S; Klein C; Hallek M; Krause G
Biomed Res Int; 2018; 2018():1023490. PubMed ID: 29750146
[TBL] [Abstract][Full Text] [Related]
4. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
5. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
7. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
Chen Z; Freedman MS
Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
[TBL] [Abstract][Full Text] [Related]
8. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
[TBL] [Abstract][Full Text] [Related]
9. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
10. Chicken-derived CD20 antibodies with potent B-cell depletion activity.
Chockalingam K; Kumar A; Song J; Chen Z
Br J Haematol; 2022 Nov; 199(4):560-571. PubMed ID: 36039695
[TBL] [Abstract][Full Text] [Related]
11. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
12. Development of a kinetic antibody-dependent cellular cytotoxicity assay.
Kamen L; Thakurta T; Myneni S; Zheng K; Chung S
J Immunol Methods; 2019 May; 468():49-54. PubMed ID: 30790564
[TBL] [Abstract][Full Text] [Related]
13. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.
Gertner-Dardenne J; Bonnafous C; Bezombes C; Capietto AH; Scaglione V; Ingoure S; Cendron D; Gross E; Lepage JF; Quillet-Mary A; Ysebaert L; Laurent G; Sicard H; Fournié JJ
Blood; 2009 May; 113(20):4875-84. PubMed ID: 19278954
[TBL] [Abstract][Full Text] [Related]
14. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
15. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
17. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
18. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
19. γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay.
Seidel UJ; Vogt F; Grosse-Hovest L; Jung G; Handgretinger R; Lang P
Front Immunol; 2014; 5():618. PubMed ID: 25520723
[TBL] [Abstract][Full Text] [Related]
20. Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.
Sanchez-Martinez D; Allende-Vega N; Orecchioni S; Talarico G; Cornillon A; Vo DN; Rene C; Lu ZY; Krzywinska E; Anel A; Galvez EM; Pardo J; Robert B; Martineau P; Hicheri Y; Bertolini F; Cartron G; Villalba M
Theranostics; 2018; 8(14):3856-3869. PubMed ID: 30083264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]